SGLT2 Inhibitors Tied to Lower Kidney Cancer Risk - Top-Institutions - MDSpire

SGLT2 Inhibitors Tied to Lower Kidney Cancer Risk

  • By

  • Andrea Surnit

  • June 9, 2026

Share

Top Institutions in Endocrinology

Brief introduction explaining scope and methodology.

  • #1

    Cleveland Clinic
    Cleveland Clinic

    Cleveland, Ohio

    Key Differentiators

    • Nephrology
    • Urology
    • Onco-Nephrology

  • #2

    Beth Israel Deaconess Medical Center
    Beth Israel Deaconess Medical Center

    Boston, Massachusetts

    Key Differentiators

    • Nephrology
    • Oncology

  • #3

    Taipei Medical University
    Taipei Medical University

    Taipei, Taipei City

    Key Differentiators

    • Nephrology

  • #4

    American Diabetes Association
    American Diabetes Association

    Arlington, Virginia

    Key Differentiators

    • Diabetes
    • Endocrinology

  • #5

    Kidney Disease: Improving Global Outcomes (KDIGO)
    Kidney Disease: Improving Global Outcomes (KDIGO)

    N/A, N/A

    Key Differentiators

    • Nephrology

Original Source(s)

SGLT2 Inhibitors Tied to Lower Kidney Cancer Risk

  • by Andrea Surnit

  • June 9, 2026

Related Content

Oral HRS-7535 Lowered A1c in Trial

Nonpeptide oral agent requires no fasting administration.

Case Report: Zoledronic acid-induced hyperprogression in oncology: a case study of RET-driven neuroendocrine carcinoma treated with Selpercatinib

Ensitrelvir Reduced COVID After Household Exposure

In SCORPIO-PEP, symptomatic COVID-19 occurred in 3% vs 9% of household contacts by day 10.